US7223744B2
(en)
*
|
1997-02-10 |
2007-05-29 |
Inspire Pharmaceuticals, Inc. |
Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
|
US6596725B2
(en)
*
|
1997-02-10 |
2003-07-22 |
Inspire Pharmaceuticals, Inc. |
Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
|
US7078391B2
(en)
*
|
1997-02-10 |
2006-07-18 |
Inspire Pharmaceuticals, Inc. |
Method of treating edematous retinal disorders
|
US6818629B2
(en)
|
1997-02-10 |
2004-11-16 |
Inspire Pharmaceuticals, Inc. |
Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
|
US6455554B1
(en)
*
|
1999-06-07 |
2002-09-24 |
Targacept, Inc. |
Oxopyridinyl pharmaceutical compositions and methods for use
|
US6576224B1
(en)
*
|
1999-07-06 |
2003-06-10 |
Sinuspharma, Inc. |
Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
|
US20020061281A1
(en)
*
|
1999-07-06 |
2002-05-23 |
Osbakken Robert S. |
Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
|
ES2425114T3
(en)
*
|
2000-03-16 |
2013-10-11 |
The Mclean Hospital Corporation |
CDP-choline and uridine for the treatment of alcohol abuse
|
US6596740B2
(en)
*
|
2000-10-24 |
2003-07-22 |
Richard L. Jones |
Nicotine mucosal spray
|
GB2381750A
(en)
*
|
2001-10-10 |
2003-05-14 |
Inspire Pharmaceuticals Inc |
Treatment for enhancing joint lubrication
|
US6852741B2
(en)
*
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
US6659985B2
(en)
|
2002-01-30 |
2003-12-09 |
Southern College Of Optometry |
Method to use transdermal administration of androgens to the adnexa of the eye
|
US7069084B2
(en)
*
|
2002-06-14 |
2006-06-27 |
Seefit Incorporated |
Method and apparatus for preventing and treating eyelid problems
|
EP1539152A4
(en)
*
|
2002-08-02 |
2006-10-18 |
Nutraceutical Dev Corp |
Development of muscle mass in a mammal
|
US7179481B2
(en)
*
|
2002-09-19 |
2007-02-20 |
Kimberly-Clark Worldwide, Inc. |
Vaginal health products
|
CA2502600A1
(en)
*
|
2002-10-18 |
2004-05-06 |
Molichem Medicines, Inc. |
Methods of treating dry eye disease with lantibiotics
|
ES2427347T3
(en)
*
|
2002-11-08 |
2013-10-30 |
The Mclean Hospital Corporation |
Compounds for the treatment of tobacco dependence and withdrawal
|
US7098189B2
(en)
*
|
2002-12-16 |
2006-08-29 |
Kimberly-Clark Worldwide, Inc. |
Wound and skin care compositions
|
US7056889B2
(en)
|
2002-12-16 |
2006-06-06 |
Kimberly-Clark, Worldwide, Inc. |
Compounds that bind P2Y2 or P2Y1 receptors
|
US20040176316A1
(en)
*
|
2002-12-20 |
2004-09-09 |
Renshaw Perry F. |
Compounds for the normalization of the sleep/wake cycle
|
KR20120035220A
(en)
*
|
2003-01-22 |
2012-04-13 |
센주 세이야꾸 가부시키가이샤 |
Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
|
US20050013806A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Chang Min S. |
Use of contact lens for corneal cell transplant
|
US20050255144A1
(en)
*
|
2003-04-09 |
2005-11-17 |
Directcontact Llc |
Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
|
US9216106B2
(en)
*
|
2003-04-09 |
2015-12-22 |
Directcontact Llc |
Device and method for the delivery of drugs for the treatment of posterior segment disease
|
US20050074497A1
(en)
*
|
2003-04-09 |
2005-04-07 |
Schultz Clyde L. |
Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
|
US20050208102A1
(en)
*
|
2003-04-09 |
2005-09-22 |
Schultz Clyde L |
Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
|
US6984628B2
(en)
*
|
2003-07-15 |
2006-01-10 |
Allergan, Inc. |
Ophthalmic compositions comprising trefoil factor family peptides
|
WO2005086619A2
(en)
*
|
2003-10-08 |
2005-09-22 |
The Mclean Hospital Corporation |
Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
|
US20050113449A1
(en)
*
|
2003-10-08 |
2005-05-26 |
Renshaw Perry F. |
Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
|
WO2005060984A1
(en)
*
|
2003-12-12 |
2005-07-07 |
Yee Richard W |
Method and apparatus for preventing and treating eyelid problems
|
US20060270592A1
(en)
*
|
2004-03-19 |
2006-11-30 |
Ophthalmic Research Associates, Inc. |
Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
|
EP1750740A4
(en)
*
|
2004-05-06 |
2009-06-10 |
Molichem Medicines Inc |
Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
|
EP1753445A4
(en)
*
|
2004-05-06 |
2009-05-20 |
Molichem Medicines Inc |
Treatment of ocular diseases and disorders using lantibiotic compositions
|
DE602005019724D1
(en)
*
|
2004-05-21 |
2010-04-15 |
Senju Pharma Co |
OPHTHALMOLOGIC PERCUTANEOUS ABSORBENT PREPARATION CONTAINING A MUSCARIN RECEPTOR AGONIST
|
EP1752456B1
(en)
*
|
2004-06-03 |
2015-08-26 |
Senju Pharmaceutical Co., Ltd. |
Corneal perception recovery drug containing amide compound
|
US7737128B2
(en)
*
|
2004-06-10 |
2010-06-15 |
The Mclean Hospital Corporation |
Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
|
US20090215714A1
(en)
*
|
2004-06-10 |
2009-08-27 |
Perry Renshaw |
Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
|
US7485666B2
(en)
*
|
2004-06-17 |
2009-02-03 |
Kimberly-Clark Worldwide, Inc. |
Vaginal health products
|
EP1784199A4
(en)
*
|
2004-08-11 |
2010-06-23 |
Mclean Hospital Corp |
COMPOUND FOR THE TREATMENT OF DEPENDENCE, DELETION AND USE OF MARIJUANA
|
WO2006082588A2
(en)
*
|
2005-02-07 |
2006-08-10 |
Pharmalight Inc. |
Method and device for ophthalmic administration of active pharmaceutical ingredients
|
CN101232882A
(en)
*
|
2005-07-26 |
2008-07-30 |
千寿制药株式会社 |
Percutaneously absorbable ophthalmic preparation
|
FR2889847B1
(en)
|
2005-08-18 |
2007-10-05 |
Sanofi Aventis Sa |
DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO [3.2.1] OCTAVE, THEIR PREPARATION IN THERAPEUTICS.
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
AU2006294581B2
(en)
|
2005-09-27 |
2011-11-03 |
Tissuetech, Inc. |
Amniotic membrane preparations and purified compositions and methods of use
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
US20070237797A1
(en)
*
|
2006-03-28 |
2007-10-11 |
Gholam A. Peyman |
Neural Conduit Agent Dissemination
|
US20070231360A1
(en)
*
|
2006-03-28 |
2007-10-04 |
Minu, L.L.C. |
Neural conduit agent dissemination
|
US20070297991A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Minu, L.L.C. |
Neural conduit agent dissemination for smoking cessation and other applications
|
US20080107713A1
(en)
*
|
2006-11-08 |
2008-05-08 |
Orilla Werhner C |
Contact lens as a sustained drug delivery implant
|
US20080317819A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Orilla Werhner C |
Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
|
US20090004244A1
(en)
*
|
2007-06-27 |
2009-01-01 |
Orilla Werhner C |
Iris design as a drug depot for zonal drug delivery by contact lens
|
US20090004245A1
(en)
*
|
2007-06-28 |
2009-01-01 |
Orilla Werhner C |
Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
|
DE102007055046A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Fluoron Gmbh |
infusion
|
GB0724558D0
(en)
*
|
2007-12-15 |
2008-01-30 |
Sharma Anant |
Optical correction
|
JP4746714B2
(en)
*
|
2008-05-16 |
2011-08-10 |
Axis株式会社 |
Pharmaceutical composition for treating fibromyalgia
|
US20100041621A1
(en)
*
|
2008-08-15 |
2010-02-18 |
Perry Renshaw |
Methods and compositions for improving cognitive performance
|
CN102216289A
(en)
*
|
2008-10-14 |
2011-10-12 |
塞扣吉尼克斯公司 |
Nicotinic acetylcholine receptor ligands and the uses thereof
|
SG171870A1
(en)
*
|
2009-02-11 |
2011-07-28 |
Heglund A S |
A composition for buccal absorption of nicotine for the purpose of smoking cessation
|
TWI455722B
(en)
|
2010-06-04 |
2014-10-11 |
Pfizer Vaccines Llc |
Conjugates for the prevention or treatment of nicotine addiction
|
AU2011328900B2
(en)
|
2010-11-16 |
2015-03-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Systems and methods for treatment of dry eye
|
US9821159B2
(en)
|
2010-11-16 |
2017-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Stimulation devices and methods
|
JP6527305B2
(en)
*
|
2011-01-10 |
2019-06-05 |
インヴィオン, インコーポレイテッド |
Use of beta-adrenergic inverse agonists for smoking cessation
|
WO2012170905A1
(en)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
EP2748308A4
(en)
|
2011-08-26 |
2015-04-29 |
Tissuetech Inc |
METHODS OF STERILIZING TISSUE SUPPORT F RATES
|
US9132193B2
(en)
*
|
2012-11-05 |
2015-09-15 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of Slurp1 as an imunomodulatory molecule in the ocular surface
|
RU2510701C1
(en)
*
|
2012-12-19 |
2014-04-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) |
Method of treating blepharoconjunctival form of dry eye syndrome
|
WO2014138709A1
(en)
*
|
2013-03-08 |
2014-09-12 |
Oculeve, Inc. |
Devices and methods for treating dry eye in animals
|
EP2967817B1
(en)
|
2013-03-12 |
2021-03-10 |
Oculeve, Inc. |
Implant delivery devices and systems
|
CN108744272A
(en)
|
2013-04-19 |
2018-11-06 |
奥库利维公司 |
Nose stimulating apparatus and method
|
EP3689338A1
(en)
|
2014-02-25 |
2020-08-05 |
Oculeve, Inc. |
Polymer formulations for nasolacrimal stimulation
|
US9303013B2
(en)
|
2014-05-16 |
2016-04-05 |
Pfizer Inc. |
Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
|
AU2015292278B2
(en)
|
2014-07-25 |
2020-04-09 |
Oculeve, Inc. |
Stimulation patterns for treating dry eye
|
BR112017008097B1
(en)
|
2014-10-20 |
2023-03-28 |
Oyster Point Pharma, Inc |
METHOD TO TREAT EYE CONDITIONS
|
JP6735742B2
(en)
|
2014-10-22 |
2020-08-05 |
オキュリーブ, インコーポレイテッド |
Stimulator and method for the treatment of dry eye
|
EP3209370A4
(en)
|
2014-10-22 |
2018-05-30 |
Oculeve, Inc. |
Contact lens for increasing tear production
|
EP3209371A4
(en)
|
2014-10-22 |
2018-10-24 |
Oculeve, Inc. |
Implantable nasal stimulator systems and methods
|
WO2016073667A1
(en)
*
|
2014-11-05 |
2016-05-12 |
Tissuetech, Inc. |
Compositions and method for promoting nerve growth and regeneration
|
WO2016109639A2
(en)
|
2014-12-31 |
2016-07-07 |
Brown J David |
Glaucoma treatment devices and methods
|
EP3297733A1
(en)
*
|
2015-05-21 |
2018-03-28 |
Ophtalmis Monaco |
Combination of lipoic acid and taurine as osmoprotective agent
|
JP2017052723A
(en)
*
|
2015-09-10 |
2017-03-16 |
株式会社Lttバイオファーマ |
Dry eye improver
|
JP6892693B2
(en)
*
|
2015-09-30 |
2021-06-23 |
マイクロオプティクス インコーポレイテッド |
Dry eye treatment equipment and methods
|
US10426958B2
(en)
|
2015-12-04 |
2019-10-01 |
Oculeve, Inc. |
Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
|
US10252048B2
(en)
|
2016-02-19 |
2019-04-09 |
Oculeve, Inc. |
Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
|
KR102485299B1
(en)
*
|
2016-04-07 |
2023-01-06 |
오이스터 포인트 파마 인코포레이티드 |
Methods of treating eye disorders
|
MX389596B
(en)
|
2016-04-12 |
2025-03-20 |
Herrera Arturo Solis |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE NASAL AND PARANASAL MUCOSA WITH NICOTINIC-TYPE ACETYLCHOLINE RECEPTOR AGONISTS.
|
WO2017192572A1
(en)
|
2016-05-02 |
2017-11-09 |
Oculeve, Inc. |
Intranasal stimulation for treatment of meibomian gland disease and blepharitis
|
JP2020500609A
(en)
|
2016-12-02 |
2020-01-16 |
オキュリーブ, インコーポレイテッド |
Apparatus and method for dry eye prediction and treatment recommendations
|
TW202019424A
(en)
*
|
2018-07-10 |
2020-06-01 |
美商奧伊斯特普安生物製藥公司 |
Methods of treating ocular conditions
|
WO2023279162A1
(en)
*
|
2021-07-07 |
2023-01-12 |
University Of Canberra |
Methods of treatment and inhibition
|
DE102023208057A1
(en)
|
2023-08-23 |
2025-02-27 |
Ursapharm Arzneimittel Gmbh |
OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINE ACETYLCHOLINE RECEPTOR AGONIST FOR TOPICAL APPLICATION TO THE EYE IN THE PREVENTION OR TREATMENT OF EYE INFLAMMATIONS
|